| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909344 | Leukemia Research | 2009 | 8 Pages |
Abstract
ZD6474 is an orally available, small-molecule tyrosine kinase inhibitor. This study explores the effect of ZD6474 on imatinib-resistant K562 cell lines, which show markedly increased SRC family kinases (SFKs) activity. ZD6474 induces growth arrest and apoptosis of imatinib-resistant and parental K562 cells, as well as inhibition of Src activity and its downstream effectors, the anti-apoptotic Bcl-2 family. ZD6474 treatment also inhibits the activity of STAT3 and reactivation of its activity results in suppression of the anti-tumor effects of SFKs inhibitors. A single oral administration of ZD6474 produced dose-dependent inhibition of imatinib-resistant K562 cells xenograft tumors. These results suggest that clinical assessment of ZD6474 against imatinib-resistant CML is warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hong-Yun Jia, Jiang-Xue Wu, Xiao-Feng Zhu, Jie-Min Chen, Shi-Ping Yang, Hai-Jiao Yan, Li Tan, Yi-Xin Zeng, Wenlin Huang,